These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35873701)

  • 1. Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey.
    Takeda A; Tsuboi Y; Nomoto M; Mochizuki H; Hattori N
    Parkinsons Dis; 2022; 2022():3203212. PubMed ID: 35873701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice.
    Pagonabarraga J; Arbelo JM; Grandas F; Luquin MR; Martínez Martín P; Rodríguez-Oroz MC; Valldeoriola F; Kulisevsky J
    Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32197462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.
    Stocchi F; Antonini A; Berg D; Bergmans B; Jost W; Katzenschlager R; Kulisevsky J; Odin P; Valldeoriola F; Ray Chaudhuri K
    NPJ Parkinsons Dis; 2022 Feb; 8(1):17. PubMed ID: 35190544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease:
    Hattori N; Kogo Y; Koebis M; Ishida T; Suzuki I; Tsuboi Y; Nomoto M
    Front Neurol; 2021; 12():752632. PubMed ID: 35222225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
    Tsuboi Y; Hattori N; Yamamoto A; Sasagawa Y; Nomoto M;
    J Neurol Sci; 2020 Sep; 416():117012. PubMed ID: 32673884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safinamide Mesilate (Equfina
    Koebisu M; Ishida T
    Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
    Fackrell R; Carroll CB; Grosset DG; Mohamed B; Reddy P; Parry M; Chaudhuri KR; Foltynie T
    Neurodegener Dis Manag; 2018 Oct; 8(5):349-360. PubMed ID: 29975112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging approaches in Parkinson's disease - adjunctive role of safinamide.
    Müller T
    Ther Clin Risk Manag; 2016; 12():1151-60. PubMed ID: 27536120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2018 Jul; ():. PubMed ID: 30072274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
    Kogo Y; Koebis M; Kobayashi Y; Ishida T; Maeda T
    Behav Brain Res; 2023 Aug; 452():114555. PubMed ID: 37355233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A
    Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL
    Front Neurol; 2023; 14():1147008. PubMed ID: 37051060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.